Figure 1.
(A) Schematic overview of the design of the dimeric conjugate and the mode of binding of the biparatopic affibody to VEGFR2, blocking the VEGF epitope. (B) Purity determination by analytical RP-HPLC for ZVEGFR2-Bp2. (C) LC-ESI/MS mass spectrum for ZVEGFR2-Bp2. The experimentally determined mass is indicated in the spectrum. (D) Determination of refolding capacity. CD spectra before and after heat treatment to 90 °C. (E) Determination of heat stability. CD ellipticity at 221 nm as a function of temperature.